

# WEST Search History

DATE: Tuesday, December 02, 2003

## Set Name Query

side by side

*DB=DWPI; PLUR=YES; OP=ADJ*

L8 (snip or sn1p) and l5

0 L8

L7 L5 and proteasome

1 L7

L6 tongwen-wang\$.in. and (smad or smad1)

0 L6

("WANG-T".IN. | "WANG-T-T".IN. | "WANG-T-S-F".IN. |  
"WANG-T-S".IN. | "WANG-T-R".IN. | "WANG-T-P".IN. |  
"WANG-T-M".IN. | "WANG-T-K".IN. | "WANG-T-J".IN. |  
"WANG-T-L".IN. | "WANG-T-T-M".IN. | "WANG-T-T-T".IN. |  
"WANG-T-W".IN. | "WANG-T-W-Y".IN. | "WANG-T-X".IN. |  
"WANG-T-Y".IN.)!

1060 L5

L4 tongwen-wang\$.in.

0 L4

L3 wang-tongwen\$.in.

0 L3

L2 pctus0003561

0 L2

*DB=USPT; PLUR=YES; OP=ADJ*

L1 5912224.pn.

1 L1

END OF SEARCH HISTORY

**WEST****End of Result Set** [Generate Collection](#) [Print](#)

L1: Entry 1 of 1

File: USPT

Jun 15, 1999

US-PAT-NO: 5912224  
DOCUMENT-IDENTIFIER: US 5912224 A

TITLE: Methods and compositions for enhancing cellular response to TGF-.beta. ligands

DATE-ISSUED: June 15, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Donahoe; Patricia K.	Weston	MA		
Wang; Tongwen	Arlington	MA		

US-CL-CURRENT: 514/2; 424/198.1, 424/85.1, 514/12, 514/291, 530/399

## CLAIMS:

We claim:

1. A method for potentiating a cellular response, comprising:
  - (a) administering to cells which express a receptor of a Transforming Growth Factor-beta (TGF-.beta.) family ligand an effective amount of a TGF-.beta. family ligand to induce the receptor-mediated cellular response; and
  - (b) administering to said cells an effective amount of a macrolide which is a naturally occurring or synthetic FK506 or rapamycin derivative, lacks or has reduced immunosuppressive activity as compared to FK506 or rapamycin, respectively, and binds FKBP12 to potentiate the cellular response.
2. The method of claim 1, wherein said macrolide is a FK506 antagonist.
3. The method of claim 2, wherein said FK506 antagonist has the following formula: ##STR3## wherein R.sub.1 is selected from the group consisting of H, alkyl, aryl and acyl, R.sub.2 is selected from the group consisting of H and --OR.sub.5, such that R.sub.5 is selected from the group consisting of H, alkyl, aryl and acyl, R.sub.3 is selected from the group consisting of --CH.sub.2 -- and --CH.sub.2 CH.sub.2 --, and R.sub.4 is selected from the group consisting of H, alkyl, acyl and aryl.
4. The method of claim 2, wherein said FK506 antagonist has the following formula: ##STR4## wherein R.sub.1 is selected from the group consisting of H and --CH.sub.3, R.sub.2 is selected from the group consisting of H and --OH, and R.sub.3 is selected from the group consisting of --CH.sub.2 -- and --CH.sub.2 CH.sub.2 --.
5. The method of claim 2, wherein said FK506 antagonist is 15-O-desmethyl-FK520.
6. The method of claim 2, wherein said FK506 antagonist is L-685,818.
7. The method of claim 1, wherein said receptor is selected from the group consisting of R1, R2, R3, R4, ALK3, ALK6, Sax and Tkv.